Marinomed Biotech AG (MARI.VI)

Every figure this model derived for MARI.VI, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
cash 2,588,800 CashAndCashEquivalents 2024-01-01
current assets 7,135,400 CurrentAssets 2024-01-01
current liabilities 9,653,200 CurrentLiabilities 2024-01-01
equity -10,136,400 Equity 2024-01-01
interest expense 2,523,400 FinanceCosts 2023-12-31
ocf -4,528,200 CashFlowsFromUsedInOperatingActivities 2023-12-31
revenue 9,183,500 Revenue 2023-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up MARI.VI on one particular measure came for.

RatioValue
cash operating margin-55.85
current ratio0.74
current ratio reported0.74
fcf margin-49.31
interest cover-2.03
operating margin-55.85
owner earnings margin-49.31
revenue growth-18.56
revenue growth per share-18.56
roic-191.59
rule of 40-74.41
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about MARI.VI's figures. Written by the derivation as it ran, not added afterwards.